Medical/Pharmaceuticals

Acer Medical Unveils aiMed Ahead of IFA 2025, Showcasing the Future of AI in Healthcare

BERLIN, Sept. 3, 2025 /PRNewswire/ -- Acer Medical, an Acer Group company specializing in medical imaging and AI-powered healthcare solutions, unveiled aiMed, its next-generation generative AI medical documentation system at the next@acer global press conference, ahead ofIFA 2025 in Berlin. The mi...

2025-09-03 17:30 1804

DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment ofJason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developin...

2025-09-03 10:52 1702

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 ...

2025-09-02 21:10 2355

Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants

-        The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open untilNovember 20; final awardees to be announced inAugust 2026 -        Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndro...

2025-09-02 21:00 2569

Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data

* Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data * Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ --  Neurophet...

2025-09-02 21:00 2299

Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program

Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions h...

2025-09-02 21:00 1995

Desilo to Launch "HARVEST™," Encrypted Data Collaboration Platform for Healthcare, in December

SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform,HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical c...

2025-09-02 21:00 1870

BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...

2025-09-02 20:30 3681

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS fromSept. 12 - 15 in Copenhagen, Denmark: * EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrate...

2025-09-02 20:00 1284

SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift

* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...

2025-09-02 19:00 1688

Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 /PRNe...

2025-09-02 18:00 1397

Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights

SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...

2025-09-02 17:52 1490

Nuffield Holdings Welcomes Strategic Shareholders to Drive Next Phase of Regional Growth

Capital injection to accelerate M&A, AI-led operations, and expansion across Southeast Asia and the Middle East. SINGAPORE, Sept. 2, 2025 /PRNewswire/ -- Nuffield Holdings  is pleased to announce the appointment of MrLiu Song and Ms Zhang Na as new shareholde...

2025-09-02 16:45 2621

Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...

2025-09-02 16:00 1379

Jungbunzlauer to acquire from International Flavors & Fragrances, Inc. multipurpose site in Thomson, IL

 – establishing U.S. manufacturing footprint – BASEL, Switzerland, Sept. 2, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients from natural sources, announced today the signing of a binding and definitive agreement to acquire the multipurpose production ...

2025-09-02 15:00 1730

SteriLance Safety Lancets Adopted Across Thailand's Public-Hospital Channels

BANGKOK, Sept. 2, 2025 /PRNewswire/ -- SteriLance Medical announced that its safety lancet portfolio — PRESS PLUS, IMPRESS and LITE3 — has been adopted withinThailand's public-hospital channels following a tender awarded by a nationally recognized humanitarian organization. Supply and post-market...

2025-09-02 08:59 1856

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEOJames Park) today announced that it has entered a late-stage to commercial contract manufacturing par...

2025-09-02 08:00 1493

Norma Completes Quantum AI Algorithm Validation on NVIDIA

"Quantum AI up to 73x Faster on NVIDIA CUDA-Q" * Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. * By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. * The com...

2025-09-01 21:00 1778

AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction

* AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success * 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics * 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the ...

2025-09-01 21:00 1470

Data4Life announces the appointment of Dr. Ben Illigens as new CEO by the Hasso Plattner Foundation

POTSDAM, Germany, Sept. 1, 2025 /PRNewswire/ -- Data4Life announces that the Hasso Plattner Foundation, as the supporting foundation of the organization, has appointed Dr. Ben Illigens as its new Chief Executive Officer (CEO). He succeedsChristian Weiss, who has shaped the development phase of D...

2025-09-01 16:00 2746
1 ... 50515253545556 ... 646